CARDBiomedBench: A Benchmark for Evaluating Large Language Model Performance in Biomedical Research
Authors:
- Owen BianchiOBOwen Bianchi
- Maya WilleyMWMaya Willey
- Chelsea X. AlvaradoCAChelsea X. Alvarado
- Benjamin DanekBDBenjamin Danek
- Nicole KuznetsovNKNicole Kuznetsov
- Anant DaduADAnant Dadu
- Mathew J. KoretskyMKMathew J. Koretsky
- Mary B. MakariousMMMary B. Makarious
- Cory WellerCWCory Weller
- Kristin S. LevineKLKristin S. Levine
Preprint
Abstract
Backgrounds: Biomedical research requires sophisticated understanding and reasoning across multiple specializations. While large language models (LLMs) show promise in scientific applications, their capability to safely and accurately support complex biomedical research remains uncertain. Methods: We present CARDBiomedBench , a novel question-and-answer benchmark for evaluating LLMs in biomedical research. For our pilot implementation, we focus on neurodegenerative diseases (NDDs), a domain requiring integration of genetic, molecular, and clinical knowledge. The benchmark combines expert-annotated question-answer (Q/A) pairs with semi-automated data augmentation, drawing from authoritative public resources including drug development data, genome-wide association studies (GWAS), and Summary-data based Mendelian Randomization (SMR) analyses. We evaluated seven private and open-source LLMs across ten biological categories and nine reasoning skills, using novel metrics to assess both response quality and safety. Results: Our benchmark comprises over 68,000 Q/A pairs, enabling robust evaluation of LLM performance. Current state-of-the-art models show significant limitations: models like Claude-3.5-Sonnet demonstrates excessive caution (Response Quality Rate: 25% [95% CI: 25% ± 1], Safety Rate: 76% ± 1), while others like ChatGPT-4o exhibits both poor accuracy and unsafe behavior (Response Quality Rate: 37% ± 1, Safety Rate: 31% ± 1). These findings reveal fundamental gaps in LLMs’ ability to handle complex biomedical information. Conclusion: CARDBiomedBench establishes a rigorous standard for assessing LLM capabilities in biomedical research. Our pilot evaluation in the NDD domain reveals critical limitations in current models’ ability to safely and accurately process complex scientific information. Future iterations will expand to other biomedical domains, supporting the development of more reliable AI systems for accelerating scientific discovery.Keywords
All Related Versions
- Published version: The Lancet Digital Health, 8 (1), 100943.
This publication has 21 references indexed in Scilit:
- Refining the impact of genetic evidence on clinical successNature, 2024
- GeneGPT: augmenting large language models with domain tools for improved access to biomedical informationBioinformatics, 2024
- omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseasesThe American Journal of Human Genetics, 2024
- Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohortsnpj Parkinson's Disease, 2022
- Incidence of Parkinson disease in North Americanpj Parkinson's Disease, 2022
- New insights into the genetic etiology of Alzheimer’s disease and related dementiasNature Genetics, 2022
- Parkinson's diseaseThe Lancet, 2021
- Current and projected future economic burden of Parkinson’s disease in the U.S.npj Parkinson's Disease, 2020
- Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studiesThe Lancet Neurology, 2019
- Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progressionBrain, 2017